Skip to main content

Review: Coffee drinking: The rationale for treating it as a potential effect modifier of carcinogenic exposures

European Journal of Epidemiology volume 18, pages 289–298 (2003)Cite this article

Abstract

Clinical and epidemiological studies on cancer etiology seldom treat coffee drinking as a potential effect modifier. Yet caffeine exerts significant effects upon a large variety of physiologic, cellular and molecular systems. Caffeine, ‘the world's most popular drug’, is also a fundamental research tool, widely used in clinical studies on drug metabolism, and in experimental studies on cell cycle checkpoints, DNA repair, and apoptosis, among many other. Caffeine can profoundly alter cell cycle checkpoint function and several mechanisms of DNA repair, as well as carcinogen metabolism. The impact of caffeine on cell cycle checkpoint function occurs in spite of it being nonmutagenic in traditional mutagenesis assays. A complex body of biologic evidence suggests that caffeine-containing beverages can both enhance and antagonise potentially carcinogenic exposures. However, most pathways leading to the ultimate effects in human beings remain unknown. It is unclear whether any of the hundreds of compounds contained in coffee and tea exert a direct and significant carcinogenic effect per se in any human tissue at usual conditions of use. Reasons exist to consider that coffee may sometimes be an indirect, positive confounder. The study of interactions between caffeine-containing beverages and environmental agents in well defined groups of healthy and diseased people could yield new insights into checkpoint signal transduction and other mechanisms of carcinogenesis. Information on the use of caffeine-containing beverages should more often be integrated in studies on the role of gene–environment interactions in the pathogenesis of cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Kihlman BA. Caffeine and Chromosomes. Amsterdam: Elsevier, 1977.

    Google Scholar 

  2. International Agency for Research on Cancer. IARC Monographs of the Evaluation of Carcinogenic Risks to Humans, Vol. 51. Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. Lyon: International Agency for Research on Cancer, 1991.

    Google Scholar 

  3. Garattini S (ed.), Caffeine, Coffee, and Health. New York: Raven Press, 1993.

    Google Scholar 

  4. Dews PB (ed.), Caffeine. Perspectives from Recent Research. Berlin: Springer, 1984.

    Google Scholar 

  5. Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998.

    Google Scholar 

  6. Tomatis L, Aitio A, Day NE, et al. (eds), Cancer: Causes, Occurrence and Control. IARC Scientific publications, no. 100. Lyon: International Agency for Research on Cancer, 1990.

    Google Scholar 

  7. International Agency for Research on Cancer. IARC Monographs of the Evaluation of Carcinogenic Risks to Humans, Vol. 51. Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. Lyon: International Agency for Research on Cancer, 1991; 36–37, 52-57, 92, 167-174.

    Google Scholar 

  8. Rall TE. The methylxanthines. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds), Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon, 1990; 619–630.

    Google Scholar 

  9. Mohr U, Emura M, Riebe-Imre M. Experimental studies on carcinogenicity and mutagenicity of caffeine. In: Garattini S (ed.), Caffeine, Coffee, and Health. New York: Raven Press, 1993; 359–378.

    Google Scholar 

  10. Ames BN, Gold LS. The Causes and Prevention of Cancer: The Role of the Environment. Biotherapy 1998; 11: 205–220.

    Google Scholar 

  11. Ames BN, Gold LS. The Causes and Prevention of Cancer: Gaining Perspective. Environ Health Perspect 1997; 105(Suppl 4): 865–873.

    Google Scholar 

  12. Viani R. The composition of coffee. In: Garattini S (ed.), Caffeine, Coffee, and Health. New York: Raven Press, 1993; 17–41.

    Google Scholar 

  13. Spiller MA. The chemical components of coffee. In: Spiller GA (ed), Caffeine. Boca Raton: CRC, 1998; 97–161.

    Google Scholar 

  14. Mohr U, Emura M, Riebe-Imre M. Experimental studies on carcinogenicity and mutagenicity of caffeine. In: Garattini S (ed.), Caffeine, Coffee, and Health. New York: Raven Press, 1993; 359–378.

    Google Scholar 

  15. Murnane JP. Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective. Cancer Metastasis Rev 1995; 14: 17–29.

    Google Scholar 

  16. Agapova LS, Ilyinskaya GV, Turovets NA, et al. Chromosome changes caused by alterations of p53 expression. Mutat Res 1996; 354: 129–138.

    Google Scholar 

  17. DeFrank JS, Tang W, Powell SN. p53-null cells are more sensitive to ultraviolet light only in the presence of caffeine. Cancer Res 1996; 56: 5365–5368.

    Google Scholar 

  18. Muller WU, Bauch T, Wojcik A, et al. Comet assay studies indicate that caffeine-mediated increase in radiation risk of embryos is due to inhibition of DNA repair. Mutagenesis 1996; 11: 57–60.

    Google Scholar 

  19. Efferth TH, Fabry U, Glatte P, et al. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol 1995; 121: 648–656.

    Google Scholar 

  20. Link CJ Jr, Evans MK, Cook JA, et al. Caffeine inhibits gene-specific repair of UV-induced DNA damage in hamster cells and in human xeroderma pigmentosum group C cells. Carcinogenesis 1995; 16: 1149–1155.

    Google Scholar 

  21. Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW. Human DNA repair systems: An overview. Environ Molec Mutagenesis 1999; 33: 3–20.

    Google Scholar 

  22. Murnane JP. Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Mutation Res 1996; 367: 11–23.

    Google Scholar 

  23. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999; 107(Suppl 1): 5–24.

    Google Scholar 

  24. Butler J, Makeyev Y, Franklin WA. Radiosensitizing effect of wortmannin and caffeine in a human lung adenocarcinoma cell line. Proc Amer Assoc Cancer Res Annual Meeting 1999; 40: 640.

    Google Scholar 

  25. Deplanque G, Goldblum S, Vincent F, Cazenave JP, Bergerat JP, Klein-Soyer C. Caffeine does not override the G2/M block induced by UVc-radiation in normal human skin fibroblasts (NHFs). Proc Amer Assoc Cancer Res Annual Meeting 1999; 40: 143.

    Google Scholar 

  26. Rowley R. Mammalian cell-cycle responses to DNA-damaging agents. In: Nickoloff JA, Hoekstra MF (eds), DNA damage and repair. Vol. II: DNA repair in higher eukaryotes. Totowa, New Jersey: Humana Press, 1998; 465–486.

    Google Scholar 

  27. Hall-Jackson CA, Cross DA, Morrice N, Smythe C. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNAPK. Oncogene 1999; 18: 6707–6713.

    Google Scholar 

  28. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59: 4375–4382.

    Google Scholar 

  29. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822.

    Google Scholar 

  30. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogen 2001; 20: 1803–1815.

    Google Scholar 

  31. Ngheiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpoint deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 2001; 98: 9092–9097.

    Google Scholar 

  32. Spiller GA. Basic metabolism and physiological effects of the methylxanthines. In: Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998: 225–231.

    Google Scholar 

  33. Reddy CS, Hayes AW. Food-borne toxicants. In: Hayes AW (ed.), Principles and Methods of Toxicology. 3rd ed. New York: Raven, 1994; 317–360.

    Google Scholar 

  34. Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293–297.

    Google Scholar 

  35. Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K. Coffee consumption and decreased serum gamma-glutamyltransferase: A study of middle-aged Japanese men. Eur J Epidemiol 2000; 16: 419–423.

    Google Scholar 

  36. Ayalogu EO, Snelling J, Lewis DF, Talwar S, Clifford MN, Loannides C. Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: Lack of association with the Ah locus. Biochim Biophis Acta 1995; 1272: 89–94.

    Google Scholar 

  37. Bu-Abbas A, Clifford MN, Walker R, Loannides C. Modulation of hepatic cytochrome P450 activity and carcinogen bioactivation by black and decaffeinated black tea. Environ Toxicol Pharmacol 1999; 7: 41–47.

    Google Scholar 

  38. Novell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: Association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prevent 2002; 11: 377–383.

    Google Scholar 

  39. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73–77.

    Google Scholar 

  40. Carrillo JA, Benítez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127–153.

    Google Scholar 

  41. Kapuscinski J, Ardelt B, Piosik J, Zdunek M, Darzynkiewicz Z. The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine. Biochem Pharmacol 2002; 63: 625–634.

    Google Scholar 

  42. Piosik J, Zdunek M, Kapuscinski J. The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part II. The stacing complexes of caffeine with doxorubicin and mitoxantrone. Biochem Pharmacol 2002; 63: 635–646.

    Google Scholar 

  43. Conlay LA, Conant JA, deBros F, Wurtman R. Caffeine alters plasma adenosine levels. Nature 1997; 389: 136.

    Google Scholar 

  44. Carrillo JA, Benítez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293–304.

    Google Scholar 

  45. Caterson ID, Boyages SC, Brooks B, et al. Endocrine diseases. In: Speight TM, Holford NHG (eds), Avery's Drug Treatment. 4th ed. Auckland: Adis, 1997: 724–808.

    Google Scholar 

  46. Yang M, Kawamoto T, Katoh T, Mastuno K. Effects of lifestyle and geneticpolymorphisms on consumption of coffee or black tea and urinary caffeine levels. Biomarkers 1998; 3: 367–377.

    Google Scholar 

  47. Massey LK. Caffeine and the elderly. Drugs Aging 1998; 13: 43–50.

    Google Scholar 

  48. López-Abente G, González CA, Errezola M, et al. Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. Am J Epidemiol 1991; 134: 830–839.

    Google Scholar 

  49. López-Abente G, Escolar A. Tobacco consumption and bladder cancer risk in non-coffee drinkers. J Epidemiol Commun Health 2001; 55: 68–70.

    Google Scholar 

  50. Pelucchi C, Tavani A, Negri E, Franceschi S, La Vecchia C. Tobacco smoking and bladder cancer in coffee non-drinkers. J Epidemiol Commun Health 2002; 56: 78–79.

    Google Scholar 

  51. Rothman N. Genetic susceptibility biomarkers in studies of occupational and environmental cancer: methodologic issues. Toxicol Lett 1995; 77: 221–225.

    Google Scholar 

  52. Pohlabeln H, Jöckel KH, Bolm-Audor U. Non-occupational risk factors for cancer of the lower urinary tract in Germany. Eur J Epidemiol 1999; 15: 411–419.

    Google Scholar 

  53. Yang M, Kawamoto T, Katoh T, Mastuno K. Effects of lifestyle and geneticpolymorphisms on consumption of coffee or black tea and urinary caffeine levels. Biomarkers 1998; 3: 367–377.

    Google Scholar 

  54. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999; 36: 425–438.

    Google Scholar 

  55. Sala M, Cordier S, Chang-Claude J, et al. Coffee consumption and bladder cancer in nonsmokers: A pooled analysis of case-control studies in European countries. Cancer Causes Control 2000; 11: 925–931.

    Google Scholar 

  56. Escolar A, González CA, López-Abente G, et al. Bladder cancer and coffee consumption in smokers and non-smokers in Spain. Int J Epidemiol 1993; 22: 38–44.

    Google Scholar 

  57. Porta M. Epidemiologic plausibility. Br Med J, 12 Aug 1998 [electronic letter]. Available at: http://bmj.com/ cgi/eletters/317/7154/299/a#571.

  58. Porta M. Epidemiologic plausibility. Re.: ‘Biologic plausibility in causal inference: Current method and practice’. Am J Epidemiol 1999; 150: 217–218.

    Google Scholar 

  59. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9: 461–467.

    Google Scholar 

  60. Stanton CK, Gray RH. The effects of caffeine consumption on delayed conception. Am J Epidemiol 1995; 142: 1322–1329.

    Google Scholar 

  61. Szklo M, Nieto FJ. Epidemiology. Beyond the Basics. Gaisthersbrurg, MD: Aspen, 2000: 211–253.

    Google Scholar 

  62. Cnattingius S, Signorello LB, Anneren G, et al. Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med 2000; 343: 1839–1845.

    Google Scholar 

  63. Torfs CP, Christianson RE. Effect of maternal smoking and coffee consumption on the risk of having a recognized Down syndrome pregnancy. Am J Epidemiol 2000; 152: 1185–1191.

    Google Scholar 

  64. Gasior M, Jaszyna M, Munzar P, Witkin JM, Goldberg SR. Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology (Berl) 2002; 162: 385–395.

    Google Scholar 

  65. Slattery ML, Caan BJ, Anderson KE, Potter JD. Intake of fluids and methylxanthine-containing beverages: Association with colon cancer. Int J Cancer 1999; 81: 199–204.

    Google Scholar 

  66. Ngowi AV, Maeda DN, Wesseling C, Partanen TJ, Sanga MP, Mbise G. Pesticide-handling practices in agriculture in Tanzania: Observational data from 27 coffee and cotton farms. Int J Occup Environ Health 2001; 7: 326–332.

    Google Scholar 

  67. Hiramoto K, Li X, Makimoto M, Kato T, Kikugawa K. Identification of hydroxyhydroquinone in coffee as a generator of reactive oxygen species that break DNA single strands. Mutat Res 1998; 419: 43–51.

    Google Scholar 

  68. Spiller GA, Bruce B. Coffee, tea, methylxanthines, human cancer, and fibrocystic breast disease. In: Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998: 325–344.

    Google Scholar 

  69. Schwartz GG. Hypothesis: Does ochratoxin a cause testicular cancer? Cancer Causes Control 2002; 13: 91–100.

    Google Scholar 

  70. Anderson KE, Potter JD, Mack TM. Pancreatic cancer. In: Schottenfeld D, Fraumeni JF Jr (eds), Cancer epidemiology and Prevention. 2nd ed. New York: Oxford University Press, 1996; 725–771.

    Google Scholar 

  71. Graham TE. Caffeine, coffee and ephedrine: Impact on exercise performance and metabolism. Can J Appl Physiol 2001; 26(Suppl): S103–19.

    Google Scholar 

  72. Gardner C, Bruce B, Spiller GA. Coffee, caffeine and serum cholesterol. In: Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998.

    Google Scholar 

  73. Urgert R, Katan MB. The cholesterol-raising factor from coffee beans. Annu Rev Nutr 1997; 17: 305–324.

    Google Scholar 

  74. Carrillo JA, Benítez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41: 605–608.

    Google Scholar 

  75. Tanskanen A, Tuomilehto J, Viinamaki H, Vartiainen E, Lehtonen J, Puska P. Heavy coffee drinking and the risk of suicide. Eur J Epidemiol 2000; 16: 789–791.

    Google Scholar 

  76. Dews PB (ed.), Caffeine. Perspectives from Recent Research. Berlin: Springer, 1984.

  77. Garattini S. Overview. In: Garattini S, (ed.) Caffeine, Coffee, and Health. New York: Raven Press, 1993; 399–403.

    Google Scholar 

  78. Lekka NP, Paschalis C, Beratis S. Nicotine, caffeine and alcohol use in high-and low-dose benzodiazepine users. Drug Alcohol Depend 1997; 45: 207–212.

    Google Scholar 

  79. Smith BD, Tola K. Caffeine: Effects on psychological functioning and performance. In: Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998: 251–299.

    Google Scholar 

  80. Vioque J, Porta M, Quiles J, Guillén M, Ponce E. Son diferentes la dieta y los hábitos de vida de los consumidores de café. Gac Sanit 1999; 13(90): 9180.

    Google Scholar 

  81. Kozlowski LT, Henningfield JE, Keenan RM, et al. Patterns of alcohol, cigarette, and caffeine and other drug use in two drug abusing populations. J Subst Abuse Treat 1993; 10: 171–179.

    Google Scholar 

  82. Falk RT, Pickle LW, Fontham ET, et al. Life-style risk factors for pancreatic cancer in Louisiana: A case-control study. Am J Epidemiol 1988; 128: 324–336.

    Google Scholar 

  83. Schreiber GB, Robins M, Maffeo CE, et al. Confounders contributing to the reported associations of coffee or caffeine with disease. Prev Med 1988; 17: 295–309.

    Google Scholar 

  84. Kohlmeier L, DeMarini D, Piegorsch W. Gene-nutrient interactions in nutritional epidemiology. In: Margetts BM, Nelson M (eds), Design concepts in Nutritional Epidemiology. Oxford: Oxford University Press, 1997; 312–337.

    Google Scholar 

  85. Willett WC. Diet and nutrition. In: Schottenfeld D, Fraumeni JF Jr (eds), Cancer Epidemiology and Prevention. 2nd ed New York: Oxford University Press, 1996; 438–461.

    Google Scholar 

  86. Willett W. Nutritional Epidemiology. 2nd ed. Oxford: Oxford University Press, 1998; 484–496.

    Google Scholar 

  87. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds), Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon, 1990: 522–573.

    Google Scholar 

  88. Lundsberg LS. Caffeine consumption. In: Spiller GA (ed.), Caffeine. Boca Raton: CRC, 1998; 199–224.

    Google Scholar 

  89. Bailey JE. Complex systems. Lessons from metabolic engineering for functional genomics and drug discovery. Nat Biotechnol 1999; 17: 616–618.

    Google Scholar 

  90. Sjökvist F, Borga O, Dahl ML, Orme ML'E. Fundamentals of clinical pharmacology. In: Speight TM, Holford NHG (eds), Avery's Drug Treatment. 4th ed. Auckland: Adis, 1997: 1–73.

    Google Scholar 

  91. Spielberg SP, Grant DM. Pharmacogenetic and biologic markers of unintended drug effects. In: Hartzema AG, Porta M, Tilson HH (eds), Pharmacoepidemiology: An Introduction. 3rd ed. Cincinnati: Harvey Whitney Books, 1998: 161–181.

    Google Scholar 

  92. Porta M, Ayude D, Alguacil J, Jariod M. Exploring environmental causes of altered ras effects: Fragmentation plus integration? Mol Carcinog 2003; 36: 45–52.

    Google Scholar 

  93. Gavaldà L, Porta M, Malats N, et al. Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract. Gac Sanit 1995; 9: 334–342.

    Google Scholar 

  94. Porta M, Malats N, Guarner L, et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Commun Health 1999; 53: 702–709.

    Google Scholar 

  95. Vineis P. ras mutations and a cup of coffee: Cause, confounder, effect modifier, or what else? [editorial]. J Epidemiol Commun Health 1999; 53: 685.

    Google Scholar 

  96. Porta M, Malats N, Alguacil J, et al. Coffee, pancreatic cancer, and K-ras mutations: Updating the research agenda. J Epidemiol Commun Health 2000; 54: 656–659.

    Google Scholar 

  97. Abdulla S. Mocha and mutations. Nature 1999 [online] December 15. Available from: http://www.nature. com/nsu/991216/991216-9.html [last accessed 28 Nov 2002].

Download references

Author information

Authors and Affiliations

  1. Institut Municipal d'Investigació, Mèdica, Spain

    M. Porta, D. Ayude, J. Alguacil, M. Jariod, L. Ruiz & J.A. Murillo

  2. Universitat Autònoma de Barcelona, Barcelona, Spain

    M. Porta, D. Ayude & J.A. Murillo

  3. Department of Public Health, Universitat Miguel Hernández, Alacant, Spain

    J. Vioque

  4. Occupational Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    J. Alguacil

Authors
  1. M. Porta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Vioque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Ayude
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Alguacil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Jariod
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J.A. Murillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Porta, M., Vioque, J., Ayude, D. et al. Review: Coffee drinking: The rationale for treating it as a potential effect modifier of carcinogenic exposures. Eur J Epidemiol 18, 289–298 (2003). https://doi.org/10.1023/A:1023700216945

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023700216945

  • Caffeine
  • Cell cycle
  • Coffee/etiology
  • Coffee/genetics
  • Coffee/metabolism
  • Coffee/physiology
  • DNA repair
  • Epidemiology
  • Epidemiology/methods
  • Molecular
  • Mutation/genetics
  • Neoplasms/genetics